At a glance
ClinicalIndex Comparison RecordPhase 3Active· 626 enrolled
Drug / intervention
Acetylsalicylic acid +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Double-blind Placebo-controlled Study With ASA Treatment in Colorectal Cancer Patients With Mutations in the PI3K Signaling Pathway
In Brief
A Phase 3 clinical trial evaluating Acetylsalicylic acid and Placebo for Colorectal Cancer. Active but no longer recruiting, targeting 626 participants across 32 sites in 4 countries.
Detailed Summary
ALASCCA is a randomized, parallel group, double blind, multicenter, placebo-controlled, biomarker-based study of adjuvant treatment with low dose aspirin in patients with colorectal cancer. Hypothesis is that patients diagnosed with colorectal cancer and somatic mutations in PI3K pathway can significantly improve survival if treated with low dose aspirin.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Cancer
CountriesDenmark, Finland, Norway, Sweden
CollaboratorsUppsala University Hospital, Skane University Hospital
Timeline
Phase 3Active
20162017201820192020202120222023202420252026
First PostedJan 2016
Enrollment StartApr 2016
Primary CompletionAug 2024
TodayJul 2026
Study CompletionAug 2026
First PostedJan 6, 2016
Enrollment StartApr 7, 2016
Primary CompletionAug 1, 2024
Study CompletionAug 1, 2026
TodayJul 2, 2026
Enrollment to primary: 8.3 yearsPosted 10.5 years ago
Interventions
Acetylsalicylic aciddrug
Placebodrug